**Name of Journal: *World Journal of Clinical Urology***

**ESPS Manuscript NO: 25628**

**Manuscript Type: Editorial**

**Efficacy and safety of onabotulinum toxin A for overactive bladder**

Patel CK *et al*. Onabotulinum toxin A for overactive bladder

**Chintan K Patel, Arthur P Mourtzinos**

**Chintan K Patel, Arthur P Mourtzinos,** Lahey Hospital and Medical Center, Institute of Urology, Burlington, MA 01805, United States

**Author contributions:** Patel CK played an integral role in the conception of the article, acquisition of literature and also drafted the manuscript; Mourtzinos AP is the senior author who reviewed and made critical revisions to the manuscript.

**Conflict-of-interest** **statement:** The authors declare no conflicts of interest regarding this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Correspondence to: Chintan K Patel, MD, Resident** in Urology, Hospital and Medical Center, Institute of Urology, 41 Burlington Mall Rd., Burlington, MA 01805, United States. chintan.patel@lahey.org

**Telephone:** +1-781-7445100

**Received:** March 17, 2016

**Peer-review started:** March 19, 2016

**First decision:** May 17, 2016

**Revised:** May 26, 2016

**Accepted:** July 11, 2016

**Article in press:**

**Published online:**

**Abstract**

Overactive bladder (OAB) syndrome is a condition which affects 16.9% of women and 16.2% of men with a significant negative impact on quality of life. It is a condition characterized by urgency, with or without urge incontinence, frequency and nocturia. Behavioral modifications and oral anti-muscurinic medications are first and second-line therapies for OAB but are frequently ineffective or poorly tolerated. For refractory cases of OAB, onabotulinum toxin can be offered and this therapy was approved by the Food and Drug Administration in January of 2013. In this editorial, we will review the indications, usage, efficacy and safety data for intradetrusor injection of onabotulinum toxin A.

**Key words:** Onabotulinum toxin A; Botox; Overactive bladder; Overactive bladder; Neurogenic bladder; Urinary bladder; Detrusor overactivity

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Overactive bladder (OAB) remains a highly prevalent and frequently, a recalcitrant constellation of symptoms. For patients who are refractory to oral medical therapy, there is sufficient level I evidence to support the use of onabotulinum toxin A injection therapy. It is a safe and very effective 2nd line treatment for OAB, even in the elderly population. The suggested Food and Drug Administration-approved dose is 100 U to maximize the benefits and minimize the adverse effects of this therapy. Risks of the intradetrusor injection of onabotulinum toxin A include urinary tract infection, increased post void residual, urinary retention which may lead to necessity of self catherization for a period of time.

Patel CK, Mourtzinos AP. Efficacy and safety of onabotulinum toxin A for overactive bladder. *World J Clin Urol* 2016; In press

**BACKGROUND**

Overactive bladder (OAB) is defined by the International Continence Society as “urinary urgency, usually accompanied by frequency and nocturia with or without urgency urinary incontinence in the absence of pathological or metabolic conditions that might explain these symptoms”[1]. Based on the National Overactive Bladder Evaluation Program, a validated U.S national telephone survey, the overall prevalence of OAB in women is 16.9% and men is 16.2%[2]. OAB negatively impacts work productivity, mental well-being as well as sleep. These patients have significantly lower quality of life (QOL) scores compared to patients without OAB and which can lead to higher levels of depression and anxiety[3,4]. Furthermore, patients with OAB are burdened with time consuming and costly treatments for management of their bothersome symptoms[5]. The American Urological Association and the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction published a comprehensive evidence-based guideline on the diagnosis and management of OAB in 2012[6]. In this guideline, treatments are recommended in a step-wise, hierarchical fashion. First line therapies consist of behavioral therapy which may consist of bladder training, bladder control strategies, pelvic floor muscle training and fluid management. Complete symptom relief is rarely achieved with behavioral strategies alone but QOL improvement may be seen. Medications are second line therapy and by far, the most common treatment for OAB. Options include oxybutynin, solifenacin, fesoterodine, darifenacin, trospium, tolterodine as well as the newer beta3 agonists. The side effect profile of these antimuscarinics may vary slightly but overall are very similar and they can be quite bothersome for some patients. Common side effects include dry mouth, constipation, dry eyes, blurred vision, dyspepsia and impaired cognitive function[7]. The cognitive side effects can be further debilitating for the elderly, who represent a significant proportion of patients with OAB. In a study published by Brostom and Hallas[8], the continuation rates of the majority of antimuscarinics at 6 mo was less than 50%. Third line therapies of OAB after failure or discontinuation of second line treatments consist of sacral neuromodulation, peripheral tibial nerve stimulation and intradetrusor injection of onabotulinum toxin A. Intradetrusor injection of onabotulinum toxin A was approved by the Food and Drug Administration (FDA) for the management of OAB in January of 2013. This editorial will focus on the mechanism of action, delivery, efficacy and side effect profile of this therapy.

**BOTULINUM TOXIN**

Botulinum toxin is a potent neurotoxin produced from a gram positive anaerobic bacterium, Clostridium botulinum, was first isolated by van Ermengem in 1897[9]. Of the specific subtypes, botulinum toxin A has the longest duration of action and is used in clinical medicine[10]. For proper neuromuscular function and release of acetylcholine at the synapse, three proteins are required which make up the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex. The light chains of the botulinum toxin disrupt the SNARE complex by cleaving the integral proteins responsible for the exocytosis of ACh, specifically synaptobrevin, SNAP-25, and syntaxin, making attachment of the ACh vesicles to the SNARE complex and release of the ACh into the synaptic cleft impossible[11]. Further research is ongoing to further elucidate the mechanism in more detail with several other hypotheses being studied[12,13].

**INDICATIONS AND CLINICAL USE FOR ONABOTULINUM TOXIN A**

Onabotulinum toxin A was first introduced into urology as a treatment for detrusor external sphincter dyssynergia[14]. Subsequently, the FDA has approved onabotulinum toxin A injections for neurogenic detrusor overactivity as well as OAB. Onabotulinum toxin A is injected into several sites in the bladder wall *via* flexible or rigid cystoscopy in the clinic or ambulatory setting with either general or local anesthesia. Before injecting, the bladder should be filled to ensure adequate visualization. An injection needle is inserted *via* the cystoscope and the onabotulinum toxin A is then injected into the detrusor at multiple sites, usually avoiding the trigone. For an OAB patient, 100 U of onabotulinum toxin A is the approved FDA dose. The 100 U of onabotulinum toxin A is reconstituted in 10 cc of sterile saline and injected into the detrusor muscle just underneath the level of the bladder mucosa. The depth of injection is approximately 2 mm into the detrusor. If the injection site is too superficial, the patient will not have a therapeutic effect, and if placed too deep, the toxin may leak into adjacent structures. Injections can be started in the midline just above the inter-ureteric ridge and then, moving to either direction, at 0.5 cm intervals to the level of the bladder sidewall. Once the initial set of injections is completed, the surgeon can move upward 0.5 to 1 cm and start another series of injections[15]. Maximal effect of the onabotulinum toxin A injection is seen after one week.

**EFFICACY OF ONABOTULINUM TOXIN A**

The use of onabotulinum toxin A for OAB has been tremendously successful and has revolutionized treatment for this syndrome. Multiple, placebo-controlled, randomized controlled trials have shown that injection of onabotulinum toxin A is superior to placebo in both objective and subjective measurements. One of the earliest of these studies was published by Brubaker *et al*[16]. In their sample size of 43 females, they showed that local injection of 200 U onabotulinum toxin A was an effective and durable treatment for refractory overactive bladder. In 2011, Rovner *et al*[17] randomized 313 patients with OAB to double-blind intradetrusor injection with placebo or 50 to 300 U of onabotulinum toxin A. They found that changes from baseline in maximum cystometric capacity and volume at first involuntary detrusor contraction in the onabotulinum group were superior to placebo at week 12. Also, they reported continence rates of 16% in the placebo group compared to 30%-57% in the botulinum group. More recently, in 2013, two large scale randomized controlled trials were published which demonstrated onabotulinum toxin A was well tolerated and demonstrated significant and clinically relevant improvement in all aspects of OAB. Chappel *et al*[18] performed a multi-center, double-blind, randomized, placebo-controlled trial with > 270 patients in each arm. The onabotulinum toxin group had significantly decreased urinary incontinence episodes at week 12 as well as reductions from baseline in all other OAB symptoms. They reported clinically meaningful improvements from baseline in all Incontinence Quality of Life (I-QOL) and King’s Health Questionnaire (KHQ) multi-item domains indicating a positive impact on health-related quality of life. Nitti *et al*[19] reported the results of another large scale (557 patients), phase 3, placebo-controlled trial of onabotulinum toxin A in patients with OAB and urinary incontinence inadequately managed with anticholinergics. In this cohort, there was a 47.9% reduction in urinary incontinence episodes from baseline in the onabotulinum toxin A group compared to 12.5% in the placebo group. Complete continence was achieved by 22.9% of patients treated with onabotulinum toxin A compared to 6.5% of those receiving placebo. On the treatment benefit scale, 60.8% of patients in the onabotulinum group reported a positive response compared to 29.2% of patients in the placebo group. Statistically significant differences between onabotulinum toxin A and placebo were noted for all of secondary endpoints (decreases from baseline at week 12 in mean micturition, urgency, and nocturia, as well as impact on patient health-related quality of life using I-QOL and KHQ). In summation, all of these high quality studies suggest that intradetrusor injection of onabotulinum toxin A for OAB treatment is associated with significant subjective and objective improvements in OAB refractory to oral medications.

**SIDE EFFECTS OF BOTULINUM**

The most common adverse effects in trials for onabotulinum toxin A were urinary tract infection (UTI) and urinary retention necessitating clean intermittent catherization. Systemic effects are rarely observed with lower urinary tract injection of onabotulinum toxin A. However, due to its paralytic mechanism, theoretical concerns for systemic adverse effects do remain. Rare cases of generalized weakness have been reported with 300 U of onabotulinum toxin A and the reported duration of such symptoms varies from two weeks to two months[20]. Rates of UTI from published trials range from 3.6% to 54.5% with rates generally increasing in a dose dependent fashion[21]. In a more contemporary, phase III, double-blinded study, Nitti *et al*[19] reported an overall UTI rate of 15.5% in the onabotulinum toxin A group in the first 12 wk of the injection. All UTIs were uncomplicated. (In our practice, a prophylactic antibiotic is provided to the patient prior to the procedure). Urinary retention is quantified by measuring a post void residual (PVR) and the definition of an elevated PVR varies across studies, with most studies using a threshold of 150 ml. Although elevations in PVR do occur following this procedure, this does not necessitate self catherization in all patients[17,22]. Similar to the rates of UTIs, rates of urinary retention increase in a dose dependent pattern, ranging from 5% to 21.2%. In their study of 278 randomized patients who received onabotulinum toxin A, Nitti *et al*[19] reported a PVR > 200 in 8.7% of patients with an overall rate of self catherization of 6.1%. The duration of urinary retention is variable and the condition can persist for the duration of the effect of the drug as demonstrated by Visco *et al*[23]. In their study of women receiving 100 U of onabotulinum toxin, 5% of women were in retention at 2 mo, 3% at 4 mo and 1% at 6 mo. Furthermore, in patients requiring self catherization, their QOL scores were comparable to those who did not need self catherization[24]. In 2011, Kuo *et al*[25] investigated the risk factors of increasing adverse effects after onabotulinum toxin A injection in 217 patients with refractory idiopathic detrusor overactivity[25]. They performed a multivariate analysis and demonstrated that male gender and baseline PVR of > 100 mL were independent predictors of acute urinary retention. Further studies are needed to better define the risk factors predisposing patients to urinary retention and subsequent self catherization. In patients receiving multiple onabotulinum toxin A injections, their risk for urinary retention remains stable over subsequent injections. Of patients who had a successful first injection, 87% had another retention-free result after their second injection[26]. As our population is aging and due to the considerable cognitive side effects of antimuscuranics, onabotulinum toxin A injection serves as a reasonable alternative in these patients; however, the question arises whether this therapy is safe in the elderly? White *et al*[27] investigated this question and showed that this onbotulinum toxin A therapy is safe and effective in the elderly[27]. In 21 patients with a mean age of 81.2 years, they found that after a single 200 U intradetrusor injec­tion, 76% of patients showed a positive clinical response with no treatment related complications. Liao *et al*[28] performed a larger study in 2013, and subdivided 166 patients into three groups: frail elderly (61), elderly without frailty (63) and younger than 65 years (42)[28]. Frail elderly was defined as age greater than 65 years and 3 or more of these criteria: unintentional weight loss, self-reported exhaustion, weakness, slow walking speed and/or low physical activity. Even though they reported a lower long term success and higher PVR in the frail elderly group, they concluded that the safety and efficacy of the therapy was similar between elderly patients without frailty and younger patients. Based on these above studies, age in itself should not be a deterrent for receiving onabotulinum toxin A injection therapy. Lastly, there have been reports of onabotulinum toxin A resistance in a small percentage of patients undergoing repetitive treatment for non-urological conditions[29]. Concerns of treatment resistance and the role of antibody formation are currently being inves­tigated.

**SUMMARY**

OAB remains a highly prevalent and frequently, a recalcitrant constellation of symptoms. For patients who are refractory to oral medical therapy, there is sufficient level I evidence to support the use of onabotulinum toxin A injection therapy. It is a safe and very effective 2nd line treatment for OAB, even in the elderly population. The suggested FDA-approved dose is 100 U to maximize the benefits and minimize the adverse effects of this therapy. Risks of the intradetrusor injection of onabotulinum toxin A include UTI, increased PVR, urinary retention which may lead to necessity of self catherization for a period of time.

**REFERENCES**

1 **Haylen BT**, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, Monga A, Petri E, Rizk DE, Sand PK, Schaer GN. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. *Neurourol Urodyn* 2010; **29**: 4-20 [PMID: 19941278 DOI: 10.1002/nau.20798]

2 **Stewart WF**, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. *World J Urol* 2003; **20**: 327-336 [PMID: 12811491]

3 **Coyne KS**, Payne C, Bhattacharyya SK, Revicki DA, Thompson C, Corey R, Hunt TL. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. *Value Health* 2004; **7**: 455-463 [PMID: 15449637 DOI: 10.1111/j.1524-4733.2004.74008.x]

4 **Coyne KS**, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, Aiyer LP. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. *BJU Int* 2009; **103** Suppl 3: 4-11 [PMID: 19302497 DOI: 10.1111/j.1464-410x.2009.08371.x]

5 **Irwin DE**, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. *BJU Int* 2009; **103**: 202-209 [PMID: 19278532 DOI: 10.1111/j.1464-410x.2008.08036.x]

6 **Gormley EA**, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE, Scarpero HM, Tessier CD, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. *J Urol* 2012; **188**: 2455-2463 [PMID: 23098785 DOI: 10.1016/j.juro.2012.09.079]

7 **Chapple CR**, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. *Eur Urol* 2008; **54**: 543-562 [PMID: 18599186 DOI: 10.1016/j.eururo.2008.06.047]

8 **Brostrøm S**, Hallas J. Persistence of antimuscarinic drug use. *Eur J Clin Pharmacol* 2009; **65**: 309-314 [PMID: 19107469 DOI: 10.1007/s00228-008-0600-9]

9 **van Ermengem E**. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897. *Rev Infect Dis* 1897; **1**: 701-719 [PMID: 399378 DOI: 10.1007/bf02220526]

10 **Andersson KE**. New developments in the management of overactive bladder: focus on mirabegron and onabotulinumtoxinA. *Ther Clin Risk Manag* 2013; **9**: 161-170 [PMID: 23637536 DOI: 10.2147/tcrm.s33052]

11 **Chancellor MB**, Fowler CJ, Apostolidis A, de Groat WC, Smith CP, Somogyi GT, Aoki KR. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. *Nat Clin Pract Urol* 2008; **5**: 319-328 [PMID: 18461049 DOI: 10.1038/ncpuro1124]

12 **Apostolidis A**, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. *Eur Urol* 2006; **49**: 644-650 [PMID: 16426734 DOI: 10.1016/j.eururo.2005.12.010]

13 **Drake MJ**. Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity. *BJU Int* 2008; **102** Suppl 1: 11-16 [PMID: 18665973 DOI: 10.1111/j.1464-410x.2008.07822.x]

14 **Dykstra DD**, Sidi AA, Scott AB, Pagel JM, Goldish GD. Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. *J Urol* 1988; **139**: 919-922 [PMID: 3361663]

15 **Shenot PJ**, Mark JR. Intradetrusor onabotulinumtoxinA injection: how I do it. *Can J Urol* 2013; **20**: 6649-655; discussion 6655 [PMID: 23433140]

16 **Brubaker L**, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J. Refractory idiopathic urge urinary incontinence and botulinum A injection. *J Urol* 2008; **180**: 217-222 [PMID: 18499184 DOI: 10.1016/j.juro.2008.03.028]

17 **Rovner E**, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. *Neurourol Urodyn* 2011; **30**: 556-562 [PMID: 21351127 DOI: 10.1002/nau.21021]

18 **Chapple C**, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. *Eur Urol* 2013; **64**: 249-256 [PMID: 23608668 DOI: 10.1016/j.eururo.2013.04.001]

19 **Nitti VW**, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, Yan X, Haag-Molkenteller C. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. *J Urol* 2013; **189**: 2186-2193 [PMID: 23246476 DOI: 10.1016/j.juro.2012.12.022]

20 **De Laet K**, Wyndaele JJ. Adverse events after botulinum A toxin injection for neurogenic voiding disorders. *Spinal Cord* 2005; **43**: 397-399 [PMID: 15741978 DOI: 10.1038/sj.sc.3101736]

21 **Dmochowski R**, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. *J Urol* 2010; **184**: 2416-2422 [PMID: 20952013 DOI: 10.1016/j.juro.2010.08.021]

22 **Flynn MK**, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. *J Urol* 2009; **181**: 2608-2615 [PMID: 19375091 DOI: 10.1016/j.juro.2009.01.117]

23 **Visco AG**, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. *N Engl J Med* 2012; **367**: 1803-1813 [PMID: 23036134 DOI: 10.1056/nejmoa1208872]

24 **Kessler TM**, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. *Obstet Gynecol* 2009; **113**: 1046-1051 [PMID: 19384119 DOI: 10.1097/aog.0b013e3181a1f5ea]

25 **Kuo HC**, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. *Eur Urol* 2010; **58**: 919-926 [PMID: 20864251 DOI: 10.1016/j.eururo.2010.09.007]

26 **Khan S**, Kessler TM, Apostolidis A, Kalsi V, Panicker J, Roosen A, Gonzales G, Haslam C, Elneil S, Fowler CJ, Dasgupta P. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. *J Urol* 2009; **181**: 1773-1778 [PMID: 19233414 DOI: 10.1016/j.juro.2008.11.110]

27 **White WM**, Pickens RB, Doggweiler R, Klein FA. Short-term efficacy of botulinum toxin a for refractory overactive bladder in the elderly population. *J Urol* 2008; **180**: 2522-2526 [PMID: 18930481 DOI: 10.1016/j.juro.2008.08.030]

28 **Liao CH**, Kuo HC. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity. *J Urol* 2013; **189**: 1804-1810 [PMID: 23178902 DOI: 10.1016/j.juro.2012.11.089]

29 **Greene P**, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. *Mov Disord* 1994; **9**: 213-217 [PMID: 8196686 DOI: 10.1002/mds.870090216]

**P-Reviewer:** Ilie CP, Peitsidis P **S-Editor:** Qiu S **L-Editor: E-Editor:**